SUSMED, Inc.
4263.T · JPX
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.02 | -0.04 | 2.19 | 1.28 |
| FCF Yield | -4.26% | -2.64% | 0.92% | -2.22% |
| EV / EBITDA | -20.27 | -11.84 | -88.44 | -13.59 |
| Quality | ||||
| ROIC | -6.87% | -7.94% | -1.02% | -4.73% |
| Gross Margin | 97.35% | 96.58% | 98.49% | 96.73% |
| Cash Conversion Ratio | 1.45 | 0.65 | -2.03 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.45% | 2.63% | 66.25% | 108.64% |
| Free Cash Flow Growth | -81.97% | -391.30% | 146.32% | 25.72% |
| Safety | ||||
| Net Debt / EBITDA | 15.21 | 13.50 | 114.77 | 21.51 |
| Interest Coverage | 0.00 | -1,501.98 | -118.71 | -9.43 |
| Efficiency | ||||
| Inventory Turnover | 30.36 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 24.17 | 11.05 | 7.51 | 11.03 |